Article Text
Statistics from Altmetric.com
Aberrant T cell function,1 subsequently accompanied by increased tumour necrosis factor α (TNFα) levels, induces inflammatory symptoms in patients with Behçet’s disease (BD).2 Subsequently, treatment usually involves T cell-directed immunosuppressive or anti-TNFα treatment in patients with severe disease.3–7 Administration of the new human monoclonal TNFα antibody adalimumab has only been described in three patients with BD with uveitis.8 We analysed the effects of adalimumab on severe and often chronic disease in six heavily pretreated patients with BD in whom immunosuppressive therapy had failed (table 1).
- In this window
- In a new window
These patients were treated in the past with infliximab.9 Indications for anti-TNFα treatment …
Footnotes
-
Published Online 23 November 2006
-
Competing interests: PMvH has cooperated in a European study on patients with uveitis treated with infliximab that was sponsored by Centocor. JAMvL and PMvH were in part sponsored to visit the 12th international Behçet’s congress in Lisbon by Abbott BV where JAMvL presented these data to the international investigators on Behçet’s disease.